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B7-H4 is one of the most recently identiﬁed members of B7 superfamily of costimulatory molecules serving as an inhibitory
modulator of T-cell response. B7-H4 is broadly expressed in human peripheral tissues and inducibly expressed in immune cells.
The expression of B7-H4 has been observed in various types of human cancer tissues, and its soluble form has been detected in
bloodsamplesfromcancerpatients.However,itsprecisephysiologicalroleisstillelusive,asitsreceptorhasnotbeenidentiﬁedand
the expression levels are not consistent. This paper summarizes the pertinent data on the inhibitory role of B7-H4 in antitumor
immunity and its association with cancer progression and survival in human patients. The paper also discusses the clinical
signiﬁcance of investigating B7-H4 as potential markers for cancer diagnosis and prognosis, and as therapeutic targets.
1.Introduction
Activation of T lymphocytes requires two independent but
mandatory signals. The ﬁrst signal requires recognition of
the major histocompatibility complex (MHC)/antigen on
antigen presenting cells (APCs) and corresponding antigen-
speciﬁc T-cell receptor (TCR) on T cells. On the other
hand, the second signal is delivered by the binding of
costimulatory molecules and their receptors/ligands. In the
absence of the costimulatory signal, the ligation of TCR with
theMHC/antigencomplexresultsindisfunctionoranergyof
T cells. The typical costimulatory signals are rendered by the
molecules of the “classic” B7 family including CD80, CD86,
andtheir receptorCD28 andcytotoxic T lymphocyte antigen
(CTL-4), which could provide positive and/or negative
costimulatory signals in initiating T-cell response. Recently,
several B7 homologues have been identiﬁed, including B7-
H1, B7DC, B7-H2, B7-H3, B7-H4, and B7-H6. B7-H4
(also known as B7x or B7S1) is among the most recently
identiﬁed members of the B7 superfamily. It is broadly
expressed in many human tissues and cells, and is shown
to regulate adaptive immune response by inhibiting the
proliferation, activation, and cytokine production of T
cells, and host innate immune response by suppressing
growth of neutrophil progenitors. It is also expressed in
many types of human cancers, and has been used as a
negative prognostic indicator for many human tumors.
Therefore, B7-H4 represents a novel frontier of investigation
for understanding the molecular regulation of the immune
system and targeting B7-H4 may help to overcome the
inhibitory immune network in tumor environments. This
paper discusses the inhibitory role of B7-H4 in antitumor
immunity, and its association with cancer progression and
survival in human patients. It also discusses the clinical
signiﬁcance of investigating B7-H4 as potential markers for
cancer diagnosis, and prognosis, and as therapeutic targets.
2. StructureandExpressionPattern of B7-H4
B7-H4 was identiﬁed by DNA sequence homology with
other molecules of the B7 family in 2003 by three labora-
tories, which designated three diﬀerent names to the same
molecule, that is, B7S1, B7-H4, and B7x, respectively [1–
3], but now B7-H4 has been most widely used. B7-H4 is a2 Clinical and Developmental Immunology
type I transmembrane protein and has 20–30% amino acid
homology in the extracellular portion with other B7 family
members. The mouse and human amino acid sequences
of B7-H4 share approximately 87% amino acid identity
[2]. B7-H4 mRNA is widely expressed in human peripheral
tissues, including lung, testis, pancreas, prostate, placenta,
uterus, skin, muscle, intestine, stomach, kidney, liver, heart,
brain, and ovary [1–3]. However, its protein expression on
tissues seems to be limited [2, 4]. Initially, B7-H4 expression
was observed in cancer cells of colon, prostate, lung, and
ﬁbrosarcoma [3, 5], and human ovarian and lung cancer
tissues [4]. Subsequent studies from diﬀerent laboratories
have demonstrated that the expression of B7-H4 mRNA and
protein was detected in all of the 23 melanoma cell lines
[6], 5 gastric cancer cell lines [7], and 6 non-small-cell lung
cancer cell lines [8]. To date, B7-H4 expression has been
found in many diﬀerent types of human cancer tissues, and
soluble B7-H4 has also been detected in blood samples from
cancer patients. The expression pattern of B7-H4 in human
cancer tissues and its clinical signiﬁcances will be discussed
in Section 4.
B7-H4 is not expressed in na¨ ıve T and B cells, but after
stimulation by interleukin-6 (IL-6) and IL-10, B7-H4 is
induciblyexpressedinAPCs,includingdendriticcells(DCs),
monocytes and macrophages [1–3]. On the other hand,
the DC-diﬀerentiation cytokines, granulocyte/macrophage
colony-stimulating factor (GM-CSF) and IL-4, decrease
the expression of B7-H4 in these cells [9–11]. However,
interferons (INFs) appear to have minimal eﬀects on the
induction of B7-H4 expression [9–11].
In human ovarian cancer, tumor-associated regulatory T
(Treg) cells trigger macrophages to produce IL-6 and IL-10,
and these cytokines in turn stimulate APCs to express B7-H4
in an autocrine and/or paracrine manner [9]. High levels of
IL-6andIL-10,butnotGM-CSFandIL-4,aredetectedinthe
ovarian tumor microenvironment. Therefore, this dysfunc-
tional cytokine network in the tumor microenvironment
may enable APCs to express B7-H4. Interestingly, IL-4, IL-6,
IL-10 and GM-CSF have no regulatory eﬀects on the expres-
sion of B7-H4 on tumor cells, indicating that the expression
of B7-H4 in tumor cells may be functionally distinct and
diﬀerently regulated compared with APCs [9, 12].
To date, the receptor of B7-H4 has not yet been iden-
tiﬁed. B and T lymphocyte attenuator (BTLA) was initially
proposedtobethereceptorforB7-H4[5],butfurtherstudies
have not supported this proposal, as BTLA has not shown to
directly bind to B7-H4 but may inﬂuence the appearance of
an unknown receptor for B7-H4 on the Th1 cell surface [13–
15].
3. Negative Effects of B7-H4 on
Antitumor Immunity
3.1. Adaptive Immunity. B7-H4 inhibits the activation, pro-
liferation, clonal expansion of CD4+ and CD8+ T-cells, thus
suppressing the production of cytokines (IL-2, IFN-γ), and
generation of alloreactive cytotoxic T lymphocytes (CTLs)
by arresting the cell cycle in an in vitro T-cell activation
assay [1, 2, 5]. B7-H4 expressed on the surface of surrogate
APCs also inhibits the proliferation of T cells [2, 5]. In
vivo blockade of endogenous B7-H4 by a speciﬁc mAb
promoted T-cell response, indicating that B7-H4 plays an
inhibitory role in T-cell activation [2]. The inhibitory eﬀects
of B7-H4 on T-cell activation and proliferation are also
supported by the ﬁnding that acute lymphopenia-induced
homeostatic proliferation of T cells promotes antitumor
immunity. However, these cells display a severe deﬁcit in the
expression of B7-H4 as they show lower suppression by a
speciﬁc Ab against B7-H4 and fail to produce IL-10 [16]. B7-
H4-deﬁcient Balb/c mice mounted mildly augmented Th1
responses and displayed slightly lower parasite burdens upon
Leishmania major infection compared to the wild-type mice,
indicating that B7-H4 could inhibit Th1 response against
infection [17]. However, the lack of B7-H4 did not aﬀect
hypersensitive inﬂammatory responses in the airway or skin
that are induced by either Th1 or Th2 cells. Likewise, B7-
H4-deﬁcient mice developed normal CTL reaction against
viral infection [17]. These results suggest that B7-H4 may
be one of multiple negative cosignaling molecules that
collectively provide a ﬁne-tuning mechanism for T-cell-
mediated immune responses [18].
There is no direct evidence of a barrier function for B7-
H4, although it is variably glycosylated in tumor-speciﬁc
patterns, suggesting that glycosylation may be a potential
mechanism for modulating interaction of CTLs with tumor
cells [19]. A physical blockade would complement the ability
of B7-H4, when ligated to its unknown receptor on T cells,
to inhibit cytokine secretion, and proliferation of T cells
predominantly through cell cycle arrest [2].
The eﬀects of B7-H4 on B cells have not been inves-
tigated. However, enhanced B7-H4 expression on B cells
infected with Epstein-Barr virus (EBV) increased the levels
of intracellular reactive oxygen species (ROS), induced the
expression of Fas ligand, and subsequently led to Fas-
mediated and caspase-dependent apoptosis in association
with increased release of cytochrome c, apoptosis-inducing
factor (AIF), and EndoG from the mitochondria [20]. In a
subsequent study by the same group, engagement of B7-H4
signiﬁcantly reduced cell growth of EBV-positive lymphoma
cells, resulting in cell cycle arrest at G0-G1 phase via
downregulation of CDK4/6, CDK2, cyclin E/D expression,
phosphor-AKT, and phosphor-cyclin E and upregulation of
p21 expression [21]. These results suggest that B7-H4 may
be a potential target for EBV-positive lymphoma therapy.
Although not investigated, these studies may also imply
that B7-H4 could inhibit proliferation and activation, and
induce apoptosis of B cells, thus impairing the production
of immunoglobulins and contributing to the suppression of
adaptive immunity.
In addition, it has been demonstrated that tumoral
B7-H4+ macrophages and CD4+CD25+FoxP3+ Treg cells
suppressed tumor-associated antigen-speciﬁc T-cell immu-
nity [10]. The tumor-associated macrophages spontaneously
produce chemokine CCL22 to mediate Treg cell traﬃcking
into tumors, and Treg cells induce the expression of B7-H4
on APCs and macrophages [10]. It has been shown that Treg
cells induced macrophages to spontaneously produce IL-10Clinical and Developmental Immunology 3
and IL-6, which in turn stimulated B7-H4 expression on
macrophages in an autocrine manner through IL-10 and IL-
6[9].ThetwostudiessuggestthatTregcellsmayconveytheir
suppressive activity to APCs through B7-H4 induction [9].
3.2. Innate Immunity. To date, there has been only one
published study [22], which has investigated the role of
B7-H4 in innate immunity. It has been shown that the
inhibitory eﬀect of B7-H4 on innate immunity was mediated
through controlling the growth of neutrophils [22]. B7-H4
knockout mice were more resistant to infection by Listeria
monocytogenes than their littermates, suggesting that B7-
H4 plays an inhibitory role on innate immunity. Further
studies have shown that more neutrophils were observed in
peripheral organs of B7-H4 knockout mice than their litter-
mates but their bactericidal functions remained unchanged.
In vitro, B7-H4 inhibited the growth of bone marrow-
derived neutrophil progenitors, suggesting an inhibitory
function of B7-H4 in neutrophil expansion. As augmented
innate resistance is completely dependent on neutrophils,
even in the absence of adaptive immunity, the results
indicate that B7-H4 serves as a negative regulator of the
neutrophil response to infection, and provides a new target
for manipulation of innate immunity.
3.3.CancerImmunity. B7-H4hasbeenfoundtobeexpressed
at the mRNA and protein levels in many types of human
cancers and negatively correlate with poor prognosis (Refer
to Section 4). Expression of B7-H4 in human tumors is
most likely due to aberrant regulation of posttranscription
in tumors, since its cell surface protein expression is rare
in normal human tissues, though abundant B7-H4 mRNA
is detected [18]. B7-H4 was preferentially expressed in
nondividing tumor cells from human gliomas and medul-
loblastomas, and in a subset of brain tumor stem-like
CD133+ cells [23]. The CD133+ cell-initiated glioblastomas
showed a higher proliferation index than CD133− cell-
induced glioblastomas in immune-deﬁcient mice [23].
Increased B7-H4 expression in tumor cells correlated
with decreased cell apoptosis and enhanced outgrowth
of tumors in several models, including the severe com-
bined immunodeﬁciency (SCID)/Beige xenograft outgrowth
model [22]. B7-H4 has also been shown to be extensively
and variably N-glycosylated, which may serve as a “barrier”
mechanism to evade immunosurveillance [22]. As suggested
by Yi and Chen, the role of B7-H4 in tumor progression
may be to transform precancerous cells and then protect
them from immunosurveillance [18]. In addition, one
study has shown that overexpression of B7-H4 promoted
tumorigenesis of ovarian cancer in immunodeﬁcient mice
by increased proliferation rate, cell adhesion, migration, and
invasion [24], implying that B7-H4 might have a direct eﬀect
on tumorigenesis independent of immunity. In another
study, overexpression of B7-H4 on normal cells resulted in
malignant cellular transformation of epithelial cells, perhaps
by protecting the pretransformed cells from apoptosis, as
siRNA knockdown of B7-H4 on tumor cell lines in vitro
led to increased apoptosis [19]. However, the direct eﬀect of
B7-H4 on tumorigenesis has been only demonstrated in the
above two studies, thus the exact mechanisms need further
investigation.
In the tumor microenvironment, in addition to tumor
cells, tumor-inﬁltrating macrophages [9, 10] and endothelial
cells of small blood vessels [12] have also been found to
constitutively express B7-H4. B7-H4 was highly expressed
in tumor-associated macrophages in the ascites of ovarian
cancer patients and contributed to tumor progression [10].
B7-H4 blockade by antisense oligonucleotides restored the
function of macrophages to stimulate T cells and led to
tumor regression in vivo [10, 11].
4.B7-H4 ExpressioninHumanCancersand
Its Signiﬁcance
In the present paper, the clinical data in support of the
possible function of B7-H4 in antitumor immunity come
from 26 retrospective analyses on 13 types of human cancers
including the most common ones, that is, cancers of ovary,
esophagus, kidney, stomach, liver, lung, colon, pancreas,
breast and prostate, and melanoma. All relevant studies on
the expression of B7-H4 on human cancer tissues or levels
of soluble B7-H4 in human blood samples and the clinical
signiﬁcance are summarized in Table 1 [4–9, 12, 19, 23, 25–
41].AnegativecorrelationbetweenB7-H4expressionandT-
cellinﬁltrationhasbeenreported[25,32,34].However,such
c o r r e l a t i o nw a sn o to b s e r v e di nas t u d yo nm e l a n o m a[ 6].
The expression of B7-H4 has been most widely studied
in ovarian cancer. To date, ten studies have investigated the
expression of B7-H4 in ovarian cancer tissues and/or the
level of soluble B7-H4 in blood samples from the ovarian
cancer patients [4, 9, 19, 23, 28–30, 35–38]. The positive
B7-H4 expression rates in ovarian cancer tissues range from
9 to 100% as shown by immunohistochemistry. Most of
the studies have revealed the correlation between expression
levels of B7-H4 and survival, pathological types, or tumor
TNM staging. The levels of soluble B7-H4 in blood correlate
with tumor stage, poor prognosis, and pathological types,
indicating that B7-H4 may be a potential diagnostic marker
and a prognostic predictor for ovarian cancer. However, one
study did not show the similar correlation between soluble
B7-H4 levels in blood and other diagnostic markers for
ovarian cancer patients [27].
Breast cancer is the second most studied cancer for B7-
H4 expression. To date, six studies have investigated the
expression of B7-H4 in human breast cancer tissues [19, 30,
32, 33, 37], but two of which lack detailed data. In one study,
193 primary breast tumors and 246 metastatic breast tumors
were examined by immunohistochemistry and the B7-H4
p o s i t i v ee x p r e s s i o nr a t e sw e r ea sh i g ha s9 5 . 4 %i np r i m a r y
tumors and 97.6% in metastatic tumors, and the increased
expression of B7-H4 correlated with negative progesterone
receptor and HER-2/neu status [33]. Similarly, the other
two studies have demonstrated a positive expression rate of
B7-H4 mRNA and protein at 100%, determined by reverse
transcription polymerase chain reaction (RT-PCR) [41]a n d
immunohistochemistry [19], respectively.4 Clinical and Developmental Immunology
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In two studies on lung cancer, 31% [4] and 43% [8]o f
lung cancer tissues were found to express B7-H4 detected
by immunohistochemistry, respectively. In a study with 259
cases of renal cell carcinoma (RCC), 59.1% of the cancer
tissues had B7-H4 protein expression [12]. However, the B7-
H4 positive expression rate was found to be only 17.6% in
102 cases of early-stage RCC (T1), and B7-H4 expression
did not correlate with age, gender, TNM stage, lympho-
vascular invasion, or nuclear grade, but correlated with
cancer recurrence and negatively correlated with survival
[26]. 75.5% (71/94) of gastric cancer tissues were found to
express B7-H4 mRNA [7], but the B7-H4 protein positive
expression rate detected by immunohistochemistry dropped
to 44.9% in another study with 156 cases of gastric cancer
[27]. In one study with 24 cases of gastric cancer, the
positive rate was as low as only 12.5%. Although not widely
investigated, over 90% of the tissues from melanoma [6],
pancreatic ductal adenocarcinoma [31], uterine cancer [30,
34], esophageal squamous cell carcinoma [25], and prostate
cancer [5] expressed B7-H4, shown by immunohistochem-
istry. Although one study has reported that 63.6% (14/22) of
colon cancer tissues expressed B7-H4 [30], the expression of
B7-H4 was found to be less consistent [37, 41]. B7-H4 was
found to be expressed in 100% (34/34) of Brenner tumors
[40]. Although Brenner tumors are of benign feature, this
report is exceptionally included in Table 1.
Soluble B7-H4 was detected in blood samples from
patients of ovarian cancer, RCC, colon cancer, breast cancer,
lung cancer, and prostate cancer [8, 28, 29, 35–37, 39]. These
studiesindicatethatserumB7-H4maybeausefulmarkerfor
diagnosis and prognosis, but the mechanism of production
and the function of soluble B7-H4 remains unknown.
5. Potentialof B7-H4 inClinicalApplication
Because of the higher expression of B7-H4 in cancer tissues
compared with corresponding normal tissues and its close
correlation with stage, pathological types and biological
behavior of tumors, and survival of cancer patients, we
shouldpayattentiontothepotentialdiagnosticandprognos-
tic capacities of B7-H4 for identifying cancer, determining
pathologic variables, and predicting response to treatment
and survival. We believe that B7-H4 could become potent
tools to add to the oncologist’s toolbox for early diagnosing
cancer, monitoring the eﬃcacy of treatments and predicting
the prognosis. This may be possible when the expression
patterns of B7-H4 have been investigated on a larger number
of samples from diﬀerent types of cancers and from multiple
centers.
Given that B7-H4 is highly expressed in almost all
the examined cell lines from cancers of colon, prostate,
lung, and stomach, and ﬁbrosarcoma and melanomas [3–
8] and in various human cancer tissues (Table 1), it could
be hypothesized that the expression of B7-H4 represents
a mechanism of downregulating antitumor immunity, par-
ticularly T-cell response, at the level of the eﬀector cells
[5]. This paradigm calls for the development of new strate-
gies for tumor immunotherapy by targeting B7-H4 [42].
B7-H4 inhibits T-cell function [1–3, 5], indicating that B7-
H4-positive tumor cells have an advantage over the B7-
H4-negative tumor cells by downregulating T-cell-mediated
antitumor immunity. Consequently, the blockade of tumor-
associated B7-H4 could oﬀer a new therapeutic opportunity
for enhancing antitumor immunity. Eﬃcient neutralizing
antibodies speciﬁc for human B7H4 are not yet available.
Small interfering RNA (siRNA) [19] and antisense oligonu-
cleotides speciﬁc for B7-H4 [10, 11] have been used to
block B7-H4 expression. Blocking the expression of B7-H4
in tumor-associated macrophages disabled their suppressive
capacity, enabled tumor-associated antigen- (TAA-) speciﬁc
eﬀector T cells function, and suppressed tumor growth in
human ovarian cancer xenografts [10, 11]. In addition, the
expression of B7-H4 on endothelial cells of tumor vascula-
ture has also been observed in RCC tissues [12]. Although
the mechanism accounting for what signals trigger B7-H4
expression in tumor vessels remains unknown, one most
likely source could be the tumor microenvironments. Tumor
blood vessels are distinct from normal resting blood vessels,
and can be selectively destroyed without signiﬁcantly aﬀect-
ing normal vessels. Therefore, blockade and/or destruction
of tumor vasculature-associated B7-H4 might provide a dual
beneﬁcial therapy, that is, enhancement of T cell-mediated
antitumor immunity and destruction of tumor vessels.
6. Conclusions andFutureProspects
Recent data indicate that B7-H4 functions in peripheral
tissues to negatively regulate immune responses in target
organs. While its broad distribution is observed at mRNA
level, limited expression at the protein level suggests that
tight control of B7-H4 is imposed at posttranscriptional
level. Receptor identiﬁcation remains the manifest topic
and is critical for understanding the role of B7-H4, as it
is certainly essential to understand the complex role, but
continues to be diﬃcult due primarily to low receptor/ligand
aﬃnities. Therefore, more studies are required to seek and
identify the receptor for B7-H4. Increased B7-H4 expression
in tumor tissues and high levels in blood samples of cancer
patients represent a realistic opportunity to design novel
immunotherapeutic approaches by regulating the immune
response through manipulating the expression of B7-H4
and/or its receptor. B7-H4 can also serve as a useful
biomarker for cancer diagnosis and prognosis prediction,
when its expression patterns have been further investigated.
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